| 1.73 0.07 (4.22%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.03  |
1-year : | 2.37 |
| Resists | First : | 1.74 |
Second : | 2.03 |
| Pivot price | 1.14 |
|||
| Supports | First : | 1.15 |
Second : | 0.8 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.09 |
| MA(100) : | 1 |
MA(250) : | 1.11 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 96.1 |
D(3) : | 93 |
| RSI | RSI(14): 86 |
|||
| 52-week | High : | 1.94 | Low : | 0.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IFRX ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 349.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.54 - 1.55 | 1.55 - 1.56 |
| Close: | 1.72 - 1.73 | 1.73 - 1.74 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Tue, 21 Apr 2026
IFRX Reiterated by Guggenheim -- Price Target Maintained at $14 - GuruFocus
Tue, 21 Apr 2026
Guggenheim reiterates Inflarx stock rating on AAV opportunity By Investing.com - Investing.com South Africa
Sun, 19 Apr 2026
Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - MSN
Sun, 19 Apr 2026
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Thu, 09 Apr 2026
InflaRx (Nasdaq: IFRX) reports izicopan data showing no CYP3A4 time‑dependent inhibition - Stock Titan
Thu, 02 Apr 2026
InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 6.001e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 2,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.82e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 37 % |
| Return on Assets (ttm) | 898.3 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 29330 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -58.7 |
| EBITDA (p.s.) | -4.7947e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 3.84 |
| Dividend | 0 |
| Forward Dividend | 2.45e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|